Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - brentuximab vedotin - injection, powder, for solution - 50mg/vial - brentuximab vedotin 50mg/vial

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - brentuximab vedotin - powder for solution for infusion - 50mg

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastic agents - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd).adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct).adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl).adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl.cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Israel - English - Ministry of Health

takeda israel ltd - brentuximab vedotin - powder for concentrate for solution for infusion - brentuximab vedotin 50 mg/vial - brentuximab vedotin - adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following asct. adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy . adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine.adcetris is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda pharma a/s, denmark - brentuximab vedotin - powder for concentrate for solution for infusion - 50 mg

Kenya - English - Pharmacy and Poisons Board

takeda pharma a/s po box 260, dybendal alle 10 2630 taastrup - brentuximab vedotin - powder for concentrate for solution for infus - 50mg per vial - brentuximab vedotin

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - brentuximab vedotin -